NADPH oxidase inhibitor development for diabetic nephropathy through water tank model

Nox inhibitor for diabetic nephropathy

Article information

Kidney Res Clin Pract. 2022;41(Suppl 2):S89-S98

Publication date (electronic) : 2022 July 19

doi : https://doi.org/10.23876/j.krcp.21.269

Hye Eun Lee ¹^,^*

, Seunghwan Shim ²^,³^,^*

, Yongseok Choi^,²^,³

, Yun Soo Bae^,¹^,⁴

¹Celros Biotech, Seoul, Republic of Korea

²Institute of Life Science and Natural Resources, Korea University, Seoul, Republic of Korea

³Department of Biotechnology, Korea University, Seoul, Republic of Korea

⁴Department of Life Sciences, Ewha Womans University, Seoul, Republic of Korea

Correspondence: Yun Soo Bae Department of Life Sciences, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea. E-mail: baeys@ewha.ac.kr

Yongseok Choi Department of Biotechnology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. E-mail: ychoi@korea.ac.kr

*Hye Eun Lee and Seunghwan Shim contributed equally to this work as co-first authors.

Received 2021 November 13; Revised 2022 April 10; Accepted 2022 April 25.

Abstract

Oxidative stress can cause generation of uncontrolled reactive oxygen species (ROS) and lead to cytotoxic damage to cells and tissues. Recently, it has been shown that transient ROS generation can serve as a secondary messenger in receptor-mediated cell signaling. Although excessive levels of ROS are harmful, moderated levels of ROS are essential for normal physiological function. Therefore, regulating cellular ROS levels should be an important concept for development of novel therapeutics for treating diseases. The overexpression and hyperactivation of NADPH oxidase (Nox) can induce high levels of ROS, which are strongly associated with diabetic nephropathy. This review discusses the theoretical basis for development of the Nox inhibitor as a regulator of ROS homeostasis to provide emerging therapeutic opportunities for diabetic nephropathy.

Keywords: Diabetic nephropathies; Nox inhibitor; NADPH oxidases; Oxidative stress; Reactive oxygen species

Two faces of reactive oxygen species

Reactive oxygen species (ROS) encompassing superoxide anion (O₂^.–), hydrogen peroxide (H₂O₂), and hydroxyl radical (OH.) are believed to be simple by-products of aerobic respiration [1–3]. Uncontrolled and high concentrations of ROS result in oxidative stress that can lead to peroxidation of lipids, oxidation of proteins and nucleic acids, and ultimately cause cellular damage [1–3]. Therefore, ROS production should be tightly regulated during physiological events. A growing body of evidence has indicated that ROS can serve as secondary messengers in signaling transduction pathways mediated by various agonists such as growth factors, hormones, and cytokines to regulate cell growth, apoptosis, and differentiation [1–5]. It has been well established that phosphotyrosine of cellular proteins plays an essential role in cellular proliferation [6–9]. Stimulation of growth factor can result in increased tyrosine phosphorylation, leading to cell proliferation. Tyrosine phosphorylation is regulated by a balance between protein tyrosine kinase (PTK) and protein tyrosine phosphatase (PTPase). The PTPase family contains the conserved sequence Cys-X-X-X-X-X-Arg (Cys-X5-Arg, X indicates any amino acid) in an active center. Conserved cysteine residue in the active center possesses a low pKa through the positive charge of arginine residue and exists as a thiolate anion (-S^–), which is easily oxidized by H₂O₂. Oxidation of thiolate anion in PTPase is converted to sulfenic acid (-SOH), which can then induce the loss of phosphatase activity of PTPase. Oxidation of PTPase can disrupt the balance between PTK and PTPase. PTK activity is then relatively enhanced, resulting in increased tyrosine phosphorylation of target cell signaling-related proteins and cell proliferation [8,9].

Reactive oxygen species generation from mitochondrial respiratory chains

It is known that sources of ROS include the electron transport chain (ETC) in mitochondria and metabolic enzymes such as glucose oxidase, xanthine oxidase, cytochrome p450, and NADPH oxidase (Nox) [1–5,10–12]. This suggests that different complexes of cellular events are involved in ROS generation. Metabolic enzymes including cytochrome p450, glucose oxidase, and xanthine oxidase can produce a constant level of ROS generation, indicating that the ROS generation was not correlated with the pathogenesis of diabetic nephropathy (DN). In contrast to metabolic enzyme-generated ROS, mitochondrial ROS are known to account for a large proportion of total cellular ROS [13–15]. The ETC complexes are located in the mitochondrial inner membrane (respiratory complexes I–IV). Electron leakage from the mitochondrial ETC can generate superoxide, which is converted into H₂O₂ by manganese superoxide dismutase (Mn-SOD) in the mitochondrial matrix [16,17]. It has been reported that complex I and complex III of the mitochondrial ETC are major sites for ROS generation. However, kidney tissues in hyperglycemia can exhibit reduced expression of complex I and complex III of the ETC. An impaired ETC complex in diabetic conditions results in leaked electrons, leading to ROS generation. Many reports have indicated that mitochondrial Mn-SOD expression is decreased in DN. Reduction of mitochondrial Mn-SOD expression can induce the level of mitochondrial superoxide [18]. However, other reports have suggested that Mn-SOD deficiency fails to induce diabetic kidney diseases [19]. More detailed molecular studies between increased mitochondrial ROS and DN must be performed.

Regulation of NADPH oxidase activation

Nox is known to contribute to ROS generation in response to various agonists. Since the first discovery of gp91phox/Nox2 in phagocytic cells, an additional six homologues of Nox2 (Nox1, Nox3, Nox4, Nox5, dual oxidase 1 [Duox1], and dual oxidase 2 [Duox2]) have been identified in various nonphagocytic cells [4,5,12,20,21]. All seven Nox isozymes are composed of a single polypeptide. They can be divided into three types based on functional domain: 1) six transmembrane α-helical domains containing tandem heme group homologues to ferric reductase in the NH₂-terminal region; 2) flavin adenine dinucleotide (FAD)-binding site in the membrane proximal region; and 3) NADPH-binding site homologues to ferredoxin-NADP⁺ reductase in the long COOH-terminal region. Electrons from NADPH are transferred to oxygen molecules through FAD and two hemes, leading to the generation of O₂^.– and H₂O₂. Activations of Nox isozymes are regulated by unique regulatory mechanisms [4,5,22]. The Nox2 protein is required for one integral protein p22^phox; three cytosolic proteins p47^phox, p40^phox, and p67^phox; and small G-protein Rac (Fig. 1A). The p47^phox serves as a core protein in the complex. The tandem Src homology 3 (SH3) domains of p47^phox can interact with the proline-rich region (PRR) in the COOH-terminal region of the p22^phox protein, leading to membrane targeting. Meanwhile, the PRR in the COOH-terminal region of p47^phox can recruit the SH3 domain of p67^phox. Four tetratricopeptide repeats in the NH3 terminal region of p67^phox protein provide the binding site for G-protein Rac. The phox and bem1 (PB1) domain between the two SH3 domains of the p67^phox protein serves as the site for the molecular interaction of p67^phox protein with the PB1 domain of p40^phox. Interactions among an integral protein p22^phox; three cytosolic proteins p47^phox, p40^phox, and p67^phox; and Rac provide a stable protein complex of Nox2 to allow electron transfer from NADPH to O₂ (Fig. 1A).

Figure 1.

Structure and activation of Nox isozymes [22].

Regulation of Nox isozymes. (A) Nox2-p22^phox dimer associates with p47^phox, p67^phox, p40^phox, and Rac. (B) Nox1-p22^phox complex also binds to NoxO1, NoxA1, and Rac. (C) Nox4-p22^phox interacts with SH3YL1 for activation. (D and E) The EF hand motif of the N-terminus region in Nox5 and Duox1/2 isozymes binds to intracellular calcium for their activation.

Duox, dual oxidase; FAD, flavin adenine dinucleotide; Nox, NADPH oxidase; PRR, proline-rich region.

Nox1 proteins need to form a complex with integral protein p22^phox and two cytosolic proteins Nox organizer 1 (NoxO1) as the homologue of p47^phox, Nox activator 1 (NoxA1) as the homologue of p67^phox, and small G-protein Rac (Fig. 1B). The activation pattern of Nox1 is similar to that of Nox2. The PRR of p22^phox with the SH3 domain of NoxO1 can interact with the SH3 of the NoxO1 protein serving as a central scaffolding molecule in Nox1 complex formation. The PRR of NoxO1 provides a binding site for the SH3 domain of the NoxA1 protein, which contains four tetratricopeptide repeat domains in the NH2-terminal region for Rac binding sites [23]. Nox5 and Duox1/2 contain a Ca²⁺-binding EF hand domain in the NH₃-terminus region, which provides an intracellular calcium binding site resulting in their activation (Fig. 1D, E). These isozymes do not require integral or cytosolic proteins.

Since Nox4 has been identified from the kidney, many reports have indicated that Nox4 activation is associated with chronic kidney disease. In contrast to other Nox isozymes, the molecular mechanism of Nox4 activation has remained unclear other than that it requires the integral protein p22^phox (Fig. 1C). Although polymerase delta-interacting proteins2 (Poldip2) has been identified as a cytosolic activator for Nox4, the molecular mechanism for the interaction between Nox4-p22^phox and Poldip2 has not been suggested [24]. Recently, Yoo et al. [25] reported that the Ysc84p/Lsb4p, Lsb3p, and plant FYVE proteins region in the NH3 terminal region and the SH3 domain in the COOH-terminal region of SH3YL1 can interact with the Nox4-p22^phox complex to result in Nox4-dependent H₂O₂ generation (Fig. 1C). It has been demonstrated that formation of a ternary complex of p22^phox-SH3YL1-Nox4 leading to H₂O₂ generation induces severe renal failure in a lipopolysaccharide-induced acute kidney injury model. However, the regulatory mechanism by which high glucose or transforming growth factor β1 regulates the ternary complex of p22^phox-SH3YL1-Nox4 formation in fibrosis and DN remains to be determined.

Uncontrolled reactive oxygen species generation is associated with diabetic nephropathy: water tank model

A water tank has an inlet and outlet. If the amount of water entering from the inlet and exiting to the outlet is constant, a certain amount of water will always remain in the water tank (Fig. 2). ROS homeostasis including ROS generation and elimination exhibits a similar pattern to the water tank model. ROS can be generated from various cellular sources including Nox activation and mitochondrial respiratory chains, whereas ROS elimination is mediated by the action of cellular antioxidants (glutathione, uric acid, ascorbic acid [vitamin C], α-tocopherol [vitamin E], and ubiquinol [coenzyme Q]) and antioxidant enzymes (SOD, catalase, glutathione S-transferase, and peroxiredoxin) [26–30]. In a normal physiological condition, a balance between ROS generation and elimination is well regulated, and a certain amount of remaining ROS serves as secondary messengers in cell signaling. In a pathological stage, Nox isozymes and their regulating proteins are overexpressed, resulting in uncontrolled ROS generation [31–34]. As the balance of ROS homeostasis is disrupted, the level of ROS is gradually increased in the body, which is closely associated with the pathogenesis of DN [35–37]. Therefore, uncontrolled Nox activation should be suppressed by treatment with Nox inhibitor as an emerging therapy for DN (Fig. 2).

Figure 2.

Water tank model for ROS homeostasis.

ROS homeostasis including ROS generation and elimination has a similar pattern to the water tank model, which has a water inlet and outlet. Over-activation of Nox isozymes leads to uncontrolled ROS generation that can disrupt the balance of ROS homeostasis. Nox activation should be suppressed by treatment with Nox inhibitors as an emerging therapy for diabetic nephropathy.

Nox, NADPH oxidase; ROS, reactive oxygen species.

Since uncontrolled ROS generation is involved in DN, many studies on antioxidant therapies for DN have been conducted [38,39]. Thirteen independent clinical studies have shown inconsistent results, strongly indicating that the beneficial effects of antioxidants on DN progression are controversial [40–52]. Why are there so many inconclusive trials on antioxidant therapy? Several points in the clinical studies must be considered. The first point is that the supplement of antioxidants might not be enough to eliminate ROS present in the disease (Fig. 3). Since antioxidants can be distributed to the entire body, they cannot pinpoint pathogenic tissues to eliminate uncontrolled ROS. Therefore, antioxidant therapy is not sufficient for treating chronic kidney disease [38,39]. The second point is that the function of the antioxidant might be nonspecific for scavenging ROS in the entire body. This indicates that nonspecific antioxidants might eliminate appropriate ROS that could potentially play a role in the normal physiology of the human body. In contrast to antioxidants, Nox inhibitors might specifically regulate uncontrolled ROS inlets, resulting in decreasing ROS levels in the entire body to support the return of normal ROS balance (Fig. 3).

Figure 3.

Antioxidant therapies for chronic kidney disease.

Many clinical studies have shown that the beneficial effects of antioxidants on chronic kidney disease progression are controversial. Antioxidants are insufficient for removing excessive ROS. However, Nox inhibitors can control ROS levels to support return to normal ROS balance.

ROS, reactive oxygen species.

Oxidative stress in diabetic nephropathy

DN is one of the complications of diabetes and is the leading cause of renal failure resulting in end-stage renal disease [53–55]. In the early stages of DN, increasing albuminuria secretion and reduction of the glomerular filtration rate are common. Glomerular basement membrane thickening, mesangial expansion, overexpression of extracellular matrix (ECM) proteins, tubulointerstitial fibrosis, and glomerulosclerosis can contribute to the progression of DN [56–58]. Several lines of evidence suggest that oxidative stress mediated by uncontrolled ROS generation is associated with the pathogenesis of DN [37,53]. Renal oxidative stress is involved in the activation or overexpression of various Nox isozymes [37]. Previous reports have indicated that various Nox isozymes and their accessory proteins such as p22^phox, p47^phox, and p67^phox are expressed in kidney tissues [22]. Mesangial cells express Nox1, Nox2, and Nox4. Podocytes contain Nox2, Nox4, and Nox5. The upregulation of Nox4 and Nox5 plays a role in mesangial cell hypertrophy, tissue expansion, ECM protein accumulation, and apoptosis of podocytes [37]. Blood vessels in kidney tissues are composed of vascular smooth muscle cells and endothelial cells expressing Nox1, Nox4, and Nox5 known to be responsible for ROS generation in response to angiotensin Ⅱ [59]. Proximal tubule cells express Nox1, Nox4, and Nox5 isozymes [34,60,61]. Most Nox isozymes are expressed in different kidney tissues and cells [34]. Nox4 is predominantly expressed in all kidney cells [62–65]. Its expression is upregulated in diabetic conditions. Deletion of Nox4 can attenuate mesangial hypertrophy and ECM accumulation in diabetic conditions [66]. Moreover, inflammatory cytokine production and macrophage infiltration are reduced in Nox4 KO mice [31,67]. In contrast to Nox4, the function of Nox1 and Nox2 in DN is controversial [31,68,69]. Although Nox1 is associated with ROS generation and renal oxidation in diabetic conditions, the molecular function of Nox1 in the pathogenesis of DN remains unclear.

Development of Nox inhibitors for treatment of diabetic nephropathy

Many studies have demonstrated that oxidative stress plays an important role in DN. Therefore, various clinical trials for therapeutic agents regulating oxidative stress are continuously being conducted (Table 1) [70–89]. Although no effective therapy exists for treatment of DN, clinical trials for therapeutic Nox inhibitors are ongoing [88,89]. A dual Nox1/4 inhibitor GKT137831 (brand name: Setanaxib), a pyrazolopyridine compound, was developed by Genkyotexn (Stockholm, Sweden) [90]. In streptozotocin-induced diabetic ApoE^–/– mice, GKT137831 attenuated diabetic-induced glomerular damage including ECM accumulation and glomerular structural changes [31]. Moreover, it has been reported that GKT137831 regulates the reduction of mesangial matrix expansion and podocyte loss in a type Ⅰ diabetes model [33]. GKT137831 is now enrolled in a phase 2 clinical trial for type Ⅰ DN in Australia. The Ewha-18278 compound was first developed for osteoporosis treatment by Joo et al. [91]. The compound was transferred to AptaBio Corp. (Suwon, Korea) and is now referred to as APX-115 (Table 1). In db/db mice as a type II diabetes model, APX-115 suppressed mesangial expansion and urinary albumin excretion [72]. Renal Nox5 expression was highly increased in renal podocyte-specific Nox5 transgenic mice (Nox5 pod⁺). Moreover, APX-115 inhibited Nox5 expression and levels of urinary albumin and creatinine in Nox5 pod⁺ mice, indicating APX-115 as a potentially therapeutic agent for treatment of DN through inhibition of macrophage infiltration to the glomerulus, a renal inflammatory signal related to tumor necrosis factor receptor-associated factor and Nox5 expression. APX-115 is now in a phase 2 clinical trial for DN in the European Union. Rho-associated coiled-coil-containing protein kinase (ROCK) and sodium glucose cotransporter (SGLT) 2 are novel treatments for DN [74,75]. Fasudil, a ROCK inhibitor, reduced albuminuria in db/db mice. Canagliflozin, an SGLT inhibitor, is a compound under development by Mitsubishi Tanabe Pharma Corp. and has completed phase Ⅲ clinical trials in Japan. The novel compound improved renal outcomes in patients with type 2 diabetes [82]. Xanthine oxidase inhibitors and antioxidants regulating oxidative stress are summarized in Table 1.

Table 1.

Therapeutics including Nox inhibitors in diabetic nephropathy

Conclusion

Homeostasis between ROS generation and elimination plays an important role in normal physiological functions. Uncontrolled ROS generation through over-activation of Nox activity is closely associated with the pathogenesis of DN. Uncontrolled Nox activation should be suppressed by treatment with Nox inhibitors as an emerging therapy for DN. Recently, two Nox inhibitors (GKT137831 from Genkyotex and APX-115 from AptaBio) have been subjected to clinical phase II trials for DN patients. We believe that these Nox inhibitors provide new hope for DN patients.

Notes

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This work was supported by the Aging project (2017M3A9D8062955 to YSB) and Bio-SPC (2018M3A9G1075771 to YSB) funded by the National Research Foundation of Korea (NRF) and Ministry of Science and ICT, and by a grant from the Korea Health Technology R&D Project (HI21C0293 to HEL) through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare.

Authors’ contributions

Conceptualization: YSC, YSB

Writing–original draft: YSC, YSB

Writing–review & editing: All authors

All authors read and approved the final manuscript.

References

1. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signaling agents. Nat Rev Mol Cell Biol 2020;21:363–383.

2. Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem 2017;86:715–748.

3. Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res 2018;122:877–902.

4. Bae YS, Oh H, Rhee SG, Yoo YD. Regulation of reactive oxygen species generation in cell signaling. Mol Cells 2011;32:491–509.

5. Block K, Gorin Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev Cancer 2012;12:627–637.

6. Lee SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem 1998;273:15366–15372.

7. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002;9:387–399.

8. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005;121:667–670.

9. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006;312:1882–1883.

10. Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 2014;14:709–721.

11. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014;94:909–950.

12. Lambeth JD, Neish AS. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu Rev Pathol 2014;9:119–145.

13. Mise K, Galvan DL, Danesh FR. Shaping up mitochondria in diabetic nephropathy. Kidney360 2020;1:982–992.

14. Coughlan MT, Sharma K. Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease. Kidney Int 2016;90:272–279.

15. Lindblom R, Higgins G, Coughlan M, de Haan JB. Targeting mitochondria and reactive oxygen species-driven pathogenesis in diabetic nephropathy. Rev Diabet Stud 2015;12:134–156.

16. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem 2001;276:38388–38393.

17. Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria: a physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem 2001;276:38084–38089.

18. Kitada M, Xu J, Ogura Y, Monno I, Koya D. Manganese superoxide dismutase dysfunction and the pathogenesis of kidney disease. Front Physiol 2020;11:755.

19. Dugan LL, You YH, Ali SS, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 2013;123:4888–4899.

20. Vermot A, Petit-Härtlein I, Smith SM, Fieschi F. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology. Antioxidants (Basel) 2021;10:890.

21. Moghadam ZM, Henneke P, Kolter J. From flies to men: ROS and the NADPH oxidase in phagocytes. Front Cell Dev Biol 2021;9:628991.

22. Lee SR, An EJ, Kim J, Bae YS. Function of NADPH oxidases in diabetic nephropathy and development of Nox inhibitors. Biomol Ther (Seoul) 2020;28:25–33.

23. Cheng G, Diebold BA, Hughes Y, Lambeth JD. Nox1-dependent reactive oxygen generation is regulated by Rac1. J Biol Chem 2006;281:17718–17726.

24. Lyle AN, Deshpande NN, Taniyama Y, et al. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 2009;105:249–259.

25. Yoo JY, Cha DR, Kim B, et al. LPS-induced acute kidney injury is mediated by Nox4-SH3YL1. Cell Rep 2020;33:108245.

26. Snezhkina AV, Kudryavtseva AV, Kardymon OL, et al. ROS generation and antioxidant defense systems in normal and malignant cells. Oxid Med Cell Longev 2019;2019:6175804.

27. He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem 2017;44:532–553.

28. Rhee SG, Kil IS. Multiple functions and regulation of mammalian peroxiredoxins. Annu Rev Biochem 2017;86:749–775.

29. Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. Alexandria J Med 2018;54:287–293.

30. Michiels C, Raes M, Toussaint O, Remacle J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 1994;17:235–248.

31. Jha JC, Gray SP, Barit D, et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 2014;25:1237–1254.

32. Jiang F, Liu GS, Dusting GJ, Chan EC. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol 2014;2:267–272.

33. Gorin Y, Cavaglieri RC, Khazim K, et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 2015;308:F1276–F1287.

34. Holterman CE, Read NC, Kennedy CR. Nox and renal disease. Clin Sci (Lond) 2015;128:465–481.

35. Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 2014;63(2 Suppl 2):S63–S83.

36. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787–790.

37. Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal 2016;25:657–684.

38. Østergaard JA, Cooper ME, Jandeleit-Dahm KA. Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. J Nephrol 2020;33:917–929.

39. Bolignano D, Cernaro V, Gembillo G, Baggetta R, Buemi M, D’Arrigo G. Antioxidant agents for delaying diabetic kidney disease progression: a systematic review and meta-analysis. PLoS One 2017;12e0178699.

40. Klein F, Juhl B, Christiansen JS. Unchanged renal haemodynamics following high dose ascorbic acid administration in normoalbuminuric IDDM patients. Scand J Clin Lab Invest 1995;55:53–59.

41. Sinclair AJ, Khatieb M, Girling AJ. Reduction in diabetic microalbuminuria after short-term antioxidant therapya pilot and its pitfalls. Age Ageing 1997;26(suppl 1):P3-c-P3.

42. McAuliffe AV, Brooks BA, Fisher EJ, Molyneaux LM, Yue DK. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion. Nephron 1998;80:277–284.

43. Gaede P, Poulsen HE, Parving HH, Pedersen O. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 2001;18:756–760.

44. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25:1919–1927.

45. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005;28:2458–2464.

46. Giannini C, Lombardo F, Currò F, et al. Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus. Diabetes Metab Res Rev 2007;23:539–546.

47. Parham M, Amini M, Aminorroaya A, Heidarian E. Effect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial. Rev Diabet Stud 2008;5:102–109.

48. Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012;60:896–903.

49. Khan MI, Siddique KU, Ashfaq F, Ali W, Reddy HD, Mishra A. Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med 2013;4:336–340.

50. Noori N, Tabibi H, Hosseinpanah F, Hedayati M, Nafar M. Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. Int J Vitam Nutr Res 2013;83:77–85.

51. Haghighat N, Vafa M, Eghtesadi S, Heidari I, Hosseini A, Rostami A. The effects of tocotrienols added to canola oil on microalbuminuria, inflammation, and nitrosative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Int J Prev Med 2014;5:617–623.

52. Jadhav SS, Kuchake VG, Upasani CD. Evaluation of clinical efficacy of some antioxidants in diabetic nephropathy. Poster papers. Indian J Pharmacol 2014;46(Suppl 1):S62–S113.

53. Urner S, Ho F, Jha JC, Ziegler D, Jandeleit-Dahm K. NADPH oxidase inhibition: preclinical and clinical studies in diabetic complications. Antioxid Redox Signal 2020;33:415–434.

54. Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev 2017;33e2841.

55. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004;27 Suppl 1:S79–S83.

56. Caramori ML, Parks A, Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 2013;24:1175–1181.

57. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010;21:556–563.

58. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358–1373.

59. Wingler K, Wünsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001;31:1456–1464.

60. Yu P, Han W, Villar VA, et al. Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells. Redox Biol 2014;2:570–579.

61. Yang Y, Zhang Y, Cuevas S, et al. Paraoxonase 2 decreases renal reactive oxygen species production, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of NADPH oxidase. Free Radic Biol Med 2012;53:437–446.

62. Geiszt M, Kopp JB, Várnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 2000;97:8010–8014.

63. Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A 2009;106:14385–14390.

64. Gorin Y, Block K. Nox4 and diabetic nephropathy: with a friend like this, who needs enemies? Free Radic Biol Med 2013;61:130–142.

65. Shiose A, Kuroda J, Tsuruya K, et al. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 2001;276:1417–1423.

66. Gorin Y, Block K, Hernandez J, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005;280:39616–39626.

67. Xu Y, Ruan S, Xie H, Lin J. Role of LOX-1 in Ang II-induced oxidative functional damage in renal tubular epithelial cells. Int J Mol Med 2010;26:679–690.

68. Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2010;299:F1348–F1358.

69. You YH, Okada S, Ly S, et al. Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol 2013;304:F840–F848.

70. Gray SP, Jha JC, Kennedy K, et al. Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia 2017;60:927–937.

71. De Livera AM, Reutens A, Cooper M, et al. Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan. Trials 2020;21:459.

72. Cha JJ, Min HS, Kim KT, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest 2017;97:419–431.

73. Jin SM, Han KA, Yu JM, et al. Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade: a 16-week, randomized, double-blind, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2016;36:2108–2114.

74. Gojo A, Utsunomiya K, Taniguchi K, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007;568:242–247.

75. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008;57:714–723.

76. Afkarian M, Polsky S, Parsa A, et al. Preventing Early Renal Loss in Diabetes (PERL) Study: a randomized double-blinded trial of allopurinol-rationale, design, and baseline data. Diabetes Care 2019;42:1454–1463.

77. Klisic J, Nief V, Reyes L, Ambuhl PM. Acute and chronic regulation of the renal Na/H+ exchanger NHE3 in rats with STZ-induced diabetes mellitus. Nephron Physiol 2006;102:p27–p35.

78. Gunawardana SC, Head WS, Piston DW. Dimethyl amiloride improves glucose homeostasis in mouse models of type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E1097–E1108.

79. Persson P, Hansell P, Palm F. NADPH oxidase inhibition reduces tubular sodium transport and improves kidney oxygenation in diabetes. Am J Physiol Regul Integr Comp Physiol 2012;302:R1443–R1449.

80. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–1446.

81. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357.

82. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306.

83. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–334.

84. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327–336.

85. Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011;33:469–476.

86. Golbidi S, Ebadi SA, Laher I. Antioxidants in the treatment of diabetes. Curr Diabetes Rev 2011;7:106–125.

87. Liu S, Lee IM, Song Y, et al. Vitamin E and risk of type 2 diabetes in the women’s health study randomized controlled trial. Diabetes 2006;55:2856–2862.

88. Laddha AP, Kulkarni YA. NADPH oxidase: a membrane-bound enzyme and its inhibitors in diabetic complications. Eur J Pharmacol 2020;881:173206.

89. Elbatreek MH, Pachado MP, Cuadrado A, Jandeleit-Dahm K, Schmidt HH. Reactive oxygen comes of age: mechanism-based therapy of diabetic end-organ damage. Trends Endocrinol Metab 2019;30:312–327.

90. Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715–7730.

91. Joo JH, Oh H, Kim M, et al. NADPH oxidase 1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteasomal degradation of NoxO1 in colon cancer cells. Cancer Res 2016;76:855–865.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial and No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted non-commercial use, distribution of the material without any modifications, and reproduction in any medium, provided the original works properly cited.

Compound	Effect	Target	Clinical trials
Nox inhibitor
GKT137831	Nox1/4 inhibitor	Diabetic nephropathy [31,33,37,38,53,70]	Phase 2 trial completed (NCT0 2010242) [71]
		Atherosclerosis [70]
		Diabetic retinopathy [88]
GKT136901	Nox1/4 inhibitor	Diabetic nephropathy [37,38]
APX-115	Pan-Nox inhibitor	Diabetic nephropathy [38,53,72,88]	Phase 2 trial completed (NCT04534439)
GLX7013114	Nox4 inhibitor	Islet cell death [53]
Probucol	Nox2 inhibitor	Diabetic nephropathy [37]	Phase 2 trial completed (NCT0 1726816) [73]
Plumbagin	Nox4 inhibitor	Diabetic nephropathy [37]
ROCK inhibitor	Nox4 inhibitor	Diabetic nephropathy [37,74,75]
Statin	Rac1 inhibitor	Diabetic nephropathy [37]
PKC inhibitor	P47^phox inhibitor	Diabetic nephropathy [37]	Phase 1 trial completed (NCT0 0552227)
Apocynin	P47^phox inhibitor	Diabetic nephropathy [37]
XO inhibitor
Allopurinol	XO inhibitor	Diabetic nephropathy [38,89]	Phase 4 trial completed (NCT02829177) [76]
Febuxostat	XO inhibitor	Diabetic nephropathy [38]
NHE3 inhibitor
HOE-642	NHE3 inhibitor	Type 1 diabetes [77]
Dimethyl amiloride	NHE3 inhibitor	Type 2 diabetes [78,79]
SGLT2 inhibitor
Dapagliflozin	SGLT2 inhibitor	Type 2 diabetes [38]	Phase 3 trial completed (NCT0 3036150) [80,81]
Canagliflozin	SGLT2 inhibitor	Diabetic nephropathy [38]	Phase 3 trial completed (NCT0 3436693) [82]
Empagliflozin	SGLT2 inhibitor	Type 2 diabetes [38]	Phase 3 trial completed (NCT0 1131676) [83]
Antioxidant
Bardoxolone	Nrf2 activator	Type 2 diabetes [38,89]	Phase 2 trial completed (NCT0 0811889) [84,85]
Vitamin E	Antioxidant	Diabetic nephropathy [37,86]	Phase 3 trial terminated (NCT0 0220831) [43,87]
Coenzyme Q10	Antioxidant	Type 2 diabetes [37,86]